Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wadler

Showing results (31-40 of 140) with videos related to

Pageof 14
Sort By:
Medical Oncology (Northwood, London, England)|March 1, 1995
Modulation of 5-fluorouracil by interferon: a review of potential cellular targetsR Horowitz, E L Schwartz, S Wadler
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1997
Detection of occult gastric carcinoma with indium-111 labeled CYT-103 (Oncoscint) immunoscintigraphyE Kruglyak, L M Freeman, S Wadler
Oncology Nursing Forum|November 1, 1989
Clinical toxicities of the combination of 5-fluorouracil and recombinant interferon alfa-2a: an unusual toxicity profileS Wadler, A Lyver, P H Wiernik
American Journal of Therapeutics|May 1, 1997
A review of the clinical experience with irinotecan (CPT-11)R W Horowitz, S Wadler, P H Wiernik
Journal of Clinical Pharmacology|May 1, 1987
Phase I and II agents in cancer therapy: two cisplatin analogues and high-dose cisplatin in hypertonic saline or with thiosulfate protectionJ Z Fuks, S Wadler, P H Wiernik
Cancer Research|March 1, 1986
Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell lineS Wadler, M D Green, F M Muggia
Antisense & Nucleic Acid Drug Development|January 25, 2000
Antisense therapeutics in oncology: points to consider in their clinical evaluationS Mani, Y Gu, S Wadler, et al.
Seminars in Oncology|March 3, 1998
Endocrine-mediated mechanisms of fatigue during treatment with interferon-alphaT H Jones, S Wadler, K H Hupart
The Yale Journal of Biology and Medicine|July 1, 1988
Biologic response modifiers in gynecologic malignanciesJ P Dutcher, S Wadler, P H Wiernik
Journal of Clinical Pharmacology|September 1, 1986
Phase I and II agents in cancer therapy: I. Anthracyclines and related compoundsS Wadler, J Z Fuks, P H Wiernik
Pageof 14

Showing results (31-40 of 140) with videos related to

Sort By:
Pageof 14
Medical Oncology (Northwood, London, England)|March 1, 1995
Modulation of 5-fluorouracil by interferon: a review of potential cellular targetsR Horowitz, E L Schwartz, S Wadler
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1997
Detection of occult gastric carcinoma with indium-111 labeled CYT-103 (Oncoscint) immunoscintigraphyE Kruglyak, L M Freeman, S Wadler
Oncology Nursing Forum|November 1, 1989
Clinical toxicities of the combination of 5-fluorouracil and recombinant interferon alfa-2a: an unusual toxicity profileS Wadler, A Lyver, P H Wiernik
American Journal of Therapeutics|May 1, 1997
A review of the clinical experience with irinotecan (CPT-11)R W Horowitz, S Wadler, P H Wiernik
Journal of Clinical Pharmacology|May 1, 1987
Phase I and II agents in cancer therapy: two cisplatin analogues and high-dose cisplatin in hypertonic saline or with thiosulfate protectionJ Z Fuks, S Wadler, P H Wiernik
Cancer Research|March 1, 1986
Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell lineS Wadler, M D Green, F M Muggia
Antisense & Nucleic Acid Drug Development|January 25, 2000
Antisense therapeutics in oncology: points to consider in their clinical evaluationS Mani, Y Gu, S Wadler, et al.
Seminars in Oncology|March 3, 1998
Endocrine-mediated mechanisms of fatigue during treatment with interferon-alphaT H Jones, S Wadler, K H Hupart
The Yale Journal of Biology and Medicine|July 1, 1988
Biologic response modifiers in gynecologic malignanciesJ P Dutcher, S Wadler, P H Wiernik
Journal of Clinical Pharmacology|September 1, 1986
Phase I and II agents in cancer therapy: I. Anthracyclines and related compoundsS Wadler, J Z Fuks, P H Wiernik
Pageof 14